Interface Biologics Inc has secured $5 million in syndicated financing as it moves into the clinical application and commercialization phase of its polymer products. The financing round for the Toronto-based biomaterials company was provided by Covington Capital, VG Partners and BDC Capital. Interface Biologics has established a strong intellectual property position for its nano-engineering biomedical polymers that cross the spectrum of medical devices. The firm also announced the appointment of Thomas Reeves as its new president and CEO. He comes to the company from medical devices company OccuLogix, where he was president and COO….